We are contrasting Cronos Group Inc. (NASDAQ:CRON) and Chimerix Inc. (NASDAQ:CMRX) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group Inc. N/A 0.00 N/A -0.03 0.00 Chimerix Inc. 4.20M 27.20 73.76M -1.55 0.00 Demonstrates Cronos Group Inc. and Chimerix Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Cronos Group Inc. and Chimerix Inc. Chimerix Inc. -1,756.19% -36.5% -34.7% Insider & Institutional Ownership
Roughly 14.62% of Cronos Group Inc. shares are owned by institutional investors while 82.3% of Chimerix Inc. are owned by institutional investors. Insiders owned roughly 6.12% of Cronos Group Inc.’s shares. Insiders Comparatively, owned 0.6% of Chimerix Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Cronos Group Inc. 40.77% 31.29% 6.45% 85.06% 277.71% 66.64% Chimerix Inc. 2.74% -5.85% -11.52% -24.89% -25.55% -27% For the past year Cronos Group Inc. has 66.64% stronger performance while Chimerix Inc. has -27% weaker performance.
On 6 of the 9 factors Cronos Group Inc. beats Chimerix Inc.
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Click here to view original web page at Cronos Group Inc. (CRON) and Chimerix Inc. (NASDAQ:CMRX) Comparison side by side